Skip to content

Efficacy and Safety of tooth whitening with Curolox™ technology and calcium phosphate in vivo: A mono-centre, uncontrolled cosmetic study

Efficacy and Safety of tooth whitening with Curolox™ technology and calcium phosphate in vivo: A mono-centre, uncontrolled cosmetic study - P11-4-HAP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00014773
Enrollment
40
Registered
2018-05-17
Start date
2014-05-26
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cosmetic application for tooth whitening

Interventions

Group 1: Application of Curolox Technology plus calcium phosphate: 1. Application on D0 done by the investiagor/study team
Between D1 and D7 home application of Curolox Technology plus calcium phosphate.

Sponsors

credentis ag
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1 Age = 18 years and = 75 years 2 Patients with sound maxillary canines and incisors: - Caries-free (buccal) - No erosion - No partial restorations (buccal) 3 At least one tooth with tooth colour of A3 or darker assessed by VITA EasyShade Note: VITA Classic Tooth Colour arrangement according to brightness values: B1, A1, B2, D2, A2, C1, C2, D4, A3, D3, B3, A3.5, B4, C3, A4, C4 4 Willing and able to understand all study-related procedures and to follow the treatment instructions 5 Willing and able to attend the on-study visits and assessments 6 Written informed consent before participation in the study

Exclusion criteria

Exclusion criteria: 1 Subjects with general tooth hypersensitivity on sugar 2 Subjects with poor oral hygiene 3 Subjects with fluorosis on study teeth 4 Concurrent participation in another clinical trial 5 Bleaching during this study

Design outcomes

Primary

MeasureTime frame
The primary efficacy outcome is the difference in tooth colour (?E) as calculated from the data obtained from VITA Easyshade from baseline D0 to 1 day after treatment (D1) with the investigational product. The primary safety endpoint is percentage and distribution of severity of Undesirable Effects and Serious Undesirable Effects related to the investigational product.

Secondary

MeasureTime frame
• The difference in tooth colour (?E) as calculated by VITA Easyshade from baseline (D0) to just after the 1th treatment (D0t), to D7, D30 of treatment with the investigational product. • The change in colour class (A1-C4) assessed by VITA Easyshade from baseline (D0) to just after the 1th treatment (D0t), to D1, D7, D30 of treatment with the investigational product. • The change in tooth brightness visually assessed by VITA Bleaching Masterguide from baseline (D0) to just after the 1th treatment (D0t), to D1, D7, D30 of treatment with the investigational product. • Subject’s satisfaction about product assessed by questionnaire from baseline (D0) to just after the 1th treatment (D0t), to D1, D7, D30 of treatment with the investigational product.

Countries

Germany

Contacts

Public ContactHans-Peter Flessa

Gemeinschaftspraxis für Zahnheilkunde

info@zahnaerzte-holzkirchen.de+49 (8024) 3033 1300

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026